CN113164403A - 胶囊制剂 - Google Patents

胶囊制剂 Download PDF

Info

Publication number
CN113164403A
CN113164403A CN201980079276.4A CN201980079276A CN113164403A CN 113164403 A CN113164403 A CN 113164403A CN 201980079276 A CN201980079276 A CN 201980079276A CN 113164403 A CN113164403 A CN 113164403A
Authority
CN
China
Prior art keywords
solid solution
peg
capsule
compound
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980079276.4A
Other languages
English (en)
Chinese (zh)
Inventor
M·R·莱莱蒂
J·P·帕沃尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemocentryx Inc
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70849818&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN113164403(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of CN113164403A publication Critical patent/CN113164403A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980079276.4A 2018-11-30 2019-11-27 胶囊制剂 Pending CN113164403A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862773848P 2018-11-30 2018-11-30
US62/773,848 2018-11-30
PCT/US2019/063547 WO2020112961A1 (en) 2018-11-30 2019-11-27 Capsule formulations

Publications (1)

Publication Number Publication Date
CN113164403A true CN113164403A (zh) 2021-07-23

Family

ID=70849818

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980079276.4A Pending CN113164403A (zh) 2018-11-30 2019-11-27 胶囊制剂

Country Status (31)

Country Link
US (4) US20200170957A1 (cg-RX-API-DMAC7.html)
EP (3) EP3886820B8 (cg-RX-API-DMAC7.html)
JP (1) JP7342124B2 (cg-RX-API-DMAC7.html)
KR (1) KR102586747B1 (cg-RX-API-DMAC7.html)
CN (1) CN113164403A (cg-RX-API-DMAC7.html)
AR (1) AR117219A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019389031B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021010285A2 (cg-RX-API-DMAC7.html)
CA (1) CA3120999C (cg-RX-API-DMAC7.html)
CL (1) CL2021001389A1 (cg-RX-API-DMAC7.html)
CY (1) CY1126079T1 (cg-RX-API-DMAC7.html)
DK (2) DK4233850T3 (cg-RX-API-DMAC7.html)
ES (2) ES2943492T3 (cg-RX-API-DMAC7.html)
FI (2) FI3886820T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20241735T1 (cg-RX-API-DMAC7.html)
HU (2) HUE069633T2 (cg-RX-API-DMAC7.html)
IL (1) IL283450B2 (cg-RX-API-DMAC7.html)
LT (2) LT4233850T (cg-RX-API-DMAC7.html)
MA (2) MA54318B1 (cg-RX-API-DMAC7.html)
MD (2) MD3886820T2 (cg-RX-API-DMAC7.html)
MX (1) MX2021006242A (cg-RX-API-DMAC7.html)
NZ (1) NZ776554A (cg-RX-API-DMAC7.html)
PL (2) PL4233850T3 (cg-RX-API-DMAC7.html)
PT (2) PT4233850T (cg-RX-API-DMAC7.html)
RS (2) RS66362B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202105572UA (cg-RX-API-DMAC7.html)
SI (2) SI4233850T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202400521T1 (cg-RX-API-DMAC7.html)
TW (1) TWI827745B (cg-RX-API-DMAC7.html)
WO (1) WO2020112961A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202103820B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113164403A (zh) 2018-11-30 2021-07-23 凯莫森特里克斯股份有限公司 胶囊制剂
KR20220098754A (ko) 2019-11-08 2022-07-12 케모센트릭스, 인크. 보체 성분 C5a 수용체의 비정질 형태
CN116529241A (zh) * 2020-10-28 2023-08-01 坎莫森特里克斯公司 治疗化脓性汗腺炎的方法
CA3192880A1 (en) * 2020-10-28 2022-05-05 Chemocentryx, Inc. Methods of treating hidradenitis suppurativa
CN116635075A (zh) * 2020-12-21 2023-08-22 坎莫森特里克斯公司 使用c5a抑制剂治疗c3肾小球病
JP2025516701A (ja) * 2022-05-19 2025-05-30 ダウ グローバル テクノロジーズ エルエルシー Bcsクラスiiの薬物の改良された可溶化のためのpegベースのインターポリマー錯体の使用
US20250164505A1 (en) * 2023-11-20 2025-05-22 Qatar Foundation For Education, Science And Community Development Detection of extracellular vesicle biomarkers for the diagnosis of autism spectrum disorder
WO2025203055A1 (en) * 2024-03-26 2025-10-02 Council Of Scientific And Industrial Research Encapsulated dihydrofolate formulation for dietary supplementation as effective nutraceutical supplement and method of preparation thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1633307A (zh) * 2002-02-14 2005-06-29 索尔瓦药物有限公司 水溶性差的活性物质的口服固溶体配方
CN101065115A (zh) * 2004-11-24 2007-10-31 默克公司 取代酰胺的液体和半固体口服药物制剂
CN103068385A (zh) * 2010-06-24 2013-04-24 凯莫森特里克斯股份有限公司 C5aR拮抗剂
CN103118681A (zh) * 2010-03-10 2013-05-22 雅培制药有限公司 固体组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005053066A1 (de) 2005-11-04 2007-05-10 Basf Ag Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen
MX363066B (es) * 2007-05-29 2019-03-07 Intrexon Corp Ligandos quirales de diacilhidrazina para modular la expresion de genes exogenos por medio de un complejo receptor de ecdisona.
JP5819730B2 (ja) 2008-12-22 2015-11-24 ケモセントリックス,インコーポレイティド C5aRアンタゴニスト
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
EP2659090B1 (en) 2010-12-27 2017-08-23 Seven Generations Energy Ltd. Methods for drilling and stimulating subterranean formations for recovering hydrocarbon and natural gas resources
CN106102716A (zh) 2014-02-05 2016-11-09 斯洛文尼亚莱柯制药股份有限公司 雄激素受体拮抗剂的固体药物组合物
JP6898229B6 (ja) 2014-09-29 2021-07-28 ケモセントリックス,インコーポレイティド C5aRアンタゴニスト製造における方法及び中間体
SG11201805828YA (en) 2016-01-14 2018-08-30 Chemocentryx Inc Method of treating c3 glomerulopathy
SG11201808625QA (en) 2016-04-04 2018-10-30 Chemocentryx Inc SOLUBLE C5aR ANTAGONISTS
DK3411400T3 (da) 2017-04-03 2021-10-11 Inflarx Gmbh Behandling af inflammatoriske sygdomme med hæmmere af c5a-aktivitet
CN111741754A (zh) 2017-10-30 2020-10-02 凯莫森特里克斯股份有限公司 作为免疫调节剂的氘代化合物
KR20200109297A (ko) 2017-10-31 2020-09-22 케모센트릭스, 인크. 소변 sCD163의 C5aR 억제제 감소
JP2021527062A (ja) 2018-06-07 2021-10-11 ケモセントリックス,インコーポレイティド ANCA関連血管炎に対するc5aアンタゴニストの投薬及び効果
CN113164403A (zh) 2018-11-30 2021-07-23 凯莫森特里克斯股份有限公司 胶囊制剂

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1633307A (zh) * 2002-02-14 2005-06-29 索尔瓦药物有限公司 水溶性差的活性物质的口服固溶体配方
US20110086844A1 (en) * 2002-02-14 2011-04-14 Solvay Pharmaceuticals B.V. Oral Solid Solution Formulation of a Poorly Water-Soluble Active Substance
CN101065115A (zh) * 2004-11-24 2007-10-31 默克公司 取代酰胺的液体和半固体口服药物制剂
CN103118681A (zh) * 2010-03-10 2013-05-22 雅培制药有限公司 固体组合物
CN103068385A (zh) * 2010-06-24 2013-04-24 凯莫森特里克斯股份有限公司 C5aR拮抗剂
US20180179160A1 (en) * 2010-06-24 2018-06-28 Chemocentryx, Inc. C5ar antagonists

Also Published As

Publication number Publication date
EP4233850A3 (en) 2023-09-20
HUE062551T2 (hu) 2023-11-28
BR112021010285A2 (pt) 2021-08-17
MA62992B1 (fr) 2025-01-31
DK3886820T3 (da) 2023-05-15
IL283450A (en) 2021-07-29
LT4233850T (lt) 2025-01-27
PL3886820T3 (pl) 2023-08-14
FI4233850T3 (fi) 2024-12-30
JP2022510304A (ja) 2022-01-26
SI4233850T1 (sl) 2025-03-31
CL2021001389A1 (es) 2021-12-24
LT3886820T (lt) 2023-06-12
US20240299306A1 (en) 2024-09-12
MX2021006242A (es) 2021-09-10
EP3886820B8 (en) 2023-05-17
RS66362B1 (sr) 2025-01-31
FI3886820T3 (fi) 2023-05-25
HRP20241735T1 (hr) 2025-02-28
ZA202103820B (en) 2026-03-25
EP3886820A1 (en) 2021-10-06
AU2019389031B2 (en) 2023-06-15
EP4233850B1 (en) 2024-10-02
AU2019389031A1 (en) 2021-06-17
ES2998858T3 (en) 2025-02-21
PT4233850T (pt) 2024-12-30
NZ776554A (en) 2024-12-20
SI3886820T1 (sl) 2023-07-31
KR102586747B1 (ko) 2023-10-06
DK4233850T3 (da) 2025-01-02
HUE069633T2 (hu) 2025-04-28
EP4487915A2 (en) 2025-01-08
CA3120999C (en) 2025-04-01
ES2943492T3 (es) 2023-06-13
PL4233850T3 (pl) 2025-03-17
WO2020112961A1 (en) 2020-06-04
EP4487915A3 (en) 2025-03-19
US20220233453A1 (en) 2022-07-28
SMT202300153T1 (it) 2023-09-06
IL283450B2 (en) 2024-06-01
MD4233850T2 (ro) 2025-02-28
TWI827745B (zh) 2024-01-01
CY1126079T1 (el) 2023-11-15
AR117219A1 (es) 2021-07-21
PT3886820T (pt) 2023-05-24
JP7342124B2 (ja) 2023-09-11
KR20210098489A (ko) 2021-08-10
SMT202400521T1 (it) 2025-01-14
US11951214B2 (en) 2024-04-09
HRP20230551T1 (hr) 2023-08-18
SG11202105572UA (en) 2021-06-29
US20250375385A1 (en) 2025-12-11
MD3886820T2 (ro) 2023-07-31
EP4233850A2 (en) 2023-08-30
EP3886820B1 (en) 2023-04-12
IL283450B1 (en) 2024-02-01
TW202038952A (zh) 2020-11-01
EP3886820A4 (en) 2022-08-24
MA54318B1 (fr) 2023-08-31
MA54318A (fr) 2021-10-06
RS64250B1 (sr) 2023-06-30
CA3120999A1 (en) 2020-06-04
US20200170957A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
JP7342124B2 (ja) カプセル製剤
CN106456556A (zh) 包含非离子性表面活性剂的新型药物组合物
CN102281871A (zh) 苯达莫司汀的口服剂型
TWI500431B (zh) 苯達莫司汀(bendamustine)的口服劑量型
RU2824998C2 (ru) Лекарственные формы в виде капсул
RU2824998C9 (ru) Лекарственные формы в виде капсул
HK40121602A (en) Capsule formulations
HK40098440A (en) Capsule formulations
HK40098440B (en) Capsule formulations
HK40060732A (en) Capsule formulations
HK40060732B (en) Capsule formulations
CN105722392A (zh) 非核苷逆转录酶抑制剂的组合物
HK1179865A (en) Oral dosage forms of bendamustine

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination